NASDAQ:KZR • US49372L2097
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KEZAR LIFE SCIENCES INC (KZR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-17 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-10-17 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-17 | Jefferies | Downgrade | Buy -> Hold |
| 2025-07-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-19 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-02 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-14 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-10-14 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-10-02 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-14 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023-10-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-05 | JonesTrading | Downgrade | Buy -> Hold |
| 2023-09-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-05-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-16 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7M | -100.00% | 6.724M | 30.357M 351.47% | 182.52M 501.25% | 280.74M 53.81% | 386.1M 37.53% | |||||||
| EBITDA YoY % growth | -53.15M -28.35% | -70.14M -31.97% | -104.171M -48.52% | N/A 15.43% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.66M -27.26% | -71.16M -30.19% | -105.237M -47.89% | -92.676M 15.30% | -58.831M 34.00% | -32.947M 44.00% | -32.98M -0.10% | -44.145M -33.85% | -36.637M 17.01% | -14.716M 59.83% | 64.766M 540.11% | 157.56M 143.28% | 256.83M 63.00% | |
| Operating Margin | N/A | N/A | -1,503.39% | N/A | N/A | N/A | N/A | N/A | -544.87% | -48.48% | 35.48% | 56.12% | 66.52% | |
| EPS YoY % growth | -10.30 -6.19% | -10.10 1.94% | -14.10 -39.60% | -6.17 20.21% | -6.95 38.20% | -3.50 49.67% | -2.64 24.52% | -3.18 -20.59% | -2.10 34.20% | -0.53 74.70% | 2.36 545.71% | 5.70 141.03% | 9.20 61.52% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.24 55.18% | -0.95 58.27% | -0.92 50.87% | -0.90 41.14% | -0.74 40.75% | -1.15 -21.54% | -1.14 -24.22% | -1.14 -26.73% | -1.13 -53.78% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.93M 40.07% | -3.03M 82.81% | -2.626M 82.01% | -2.525M 85.18% | -2.525M 80.47% | N/A | N/A | N/A | N/A |
All data in USD
10 analysts have analysed KZR and the average price target is 6.12 USD. This implies a price decrease of -17.85% is expected in the next year compared to the current price of 7.45.
KEZAR LIFE SCIENCES INC (KZR) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of KEZAR LIFE SCIENCES INC (KZR) is -1.24 USD and the consensus revenue estimate is 0 USD.